Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.
Studies determining the association between hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone metabolism are mixed. We conducted a systematic review to assess the potential impact of statins on fractures, bone mineral density and bone markers. We searched Medline, Embase, the Cochrane Library, and Federal Research in Progress (FEDRIP). Inclusion criteria consisted of human studies with measurable outcomes, which were rated as good or fair according to the United States Preventive Services Task Force (USPSTF) criteria. The effects of statins on bone mineral density (BMD), bone markers and fracture risk were independently extracted by two reviewers and were combined by use of a random-effects model. The 31 analyzed studies included 24 observational studies and seven randomized controlled trials. Overall, statin use was associated with fewer hip fractures (OR 0.60, 95% CI 0.45-0.78) and improved hip BMD (Z score 0.12, 95% CI 0.05-0.19), with a non-significant reduction in vertebral fractures and no effect on vertebral BMD. In subgroup analysis of studies that involved only women there was a reduction in hip fractures (OR 0.75, 95% CI 0.60-0.95) and improvement in hip BMD (Z score 0.11, 95% CI 0.04-0.18). Vertebral BMD was unchanged, and only one study reported on vertebral fractures, finding improvement. Statins had only small effects on bone markers, with a decrease in alkaline phosphatase [standardized mean difference (SMD) -0.18, 95% CI -0.34 to -0.01], an increase in NTX (SMD 0.39, 95% CI 0.07-0.71), with no effect on osteocalcin or CTX. The statistically significant improvement in hip fracture risk was seen only in case-control trials, not in either the eight prospective trials or the two randomized controlled trials (RCTs). Statins may have a beneficial impact on bone metabolism and fracture risk; randomized controlled trials are needed to explore this association.
Hatzigeorgiou
Christos
C
Tripler Army Medical Center, Honolulu, Hawaii, USA.
Jackson
Jeffrey L
JL
D015519:Bone Density / Q000187:drug effects*; D004812:Epidemiologic Methods; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006620:Hip Fractures / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D010024:Osteoporosis / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
MMWR Morb Mortal Wkly Rep. 1998 Nov 20;47(45):969-73
9843354
J Bone Miner Res. 2004 May;19(5):737-44
15068496
J Clin Endocrinol Metab. 2000 Mar;85(3):1137-42
10720052
Clin Chim Acta. 2001 Jun;308(1-2):133-7
11412825
Osteoporos Int. 2001;12(5):380-4
11444086
Arch Intern Med. 2002 Mar 11;162(5):537-40
11871921
JAMA. 2001 Apr 11;285(14):1850-5
11308398
Lancet. 2001 Feb 17;357(9255):509-12
11229669
Lancet. 2000 Jun 24;355(9222):2185-8
10881890
Am J Cardiol. 2002 Apr 15;89(8):901-8
11950425
Biometrics. 1994 Dec;50(4):1088-101
7786990
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Am J Prev Med. 2001 Apr;20(3 Suppl):21-35
11306229
JAMA. 2001 Apr 11;285(14):1888-9
11308404
Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):e19-23
12231575
Trends Pharmacol Sci. 1998 Jan;19(1):26-37
9509899
Bone. 2003 Apr;32(4):427-33
12689687
Ann Intern Med. 2003 Jul 15;139(2):97-104
12859159
Osteoporos Int. 2002 Jul;13(7):537-41
12111013
Biometrics. 2000 Jun;56(2):455-63
10877304
BMJ. 1996 May 18;312(7041):1254-9
8634613
Heart Dis. 2003 Jan-Feb;5(1):2-7
12549983
Circulation. 2003 Jan 21;107(2):258-63
12538425
BMC Musculoskelet Disord. 2002;3:1
11806760
Eur J Clin Invest. 2002 Aug;32(8):581-9
12190958
Am J Med. 2001 May;110(7):584-7
11343673
JAMA. 2000 Jun 28;283(24):3211-6
10866868
Nutr Metab Cardiovasc Dis. 2001 Apr;11(2):84-7
11434192
Science. 1999 Dec 3;286(5446):1946-9
10583956
Osteoporos Int. 2004 Jun;15(6):452-8
15205716
Arch Intern Med. 2004 Jan 26;164(2):146-52
14744837
Circulation. 2002 Sep 17;106(12):1447-52
12234946
J Bone Miner Res. 1998 Apr;13(4):581-9
9556058
Metabolism. 2004 Jun;53(6):744-8
15164322
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
CMAJ. 2002 Nov 12;167(10 Suppl):S1-34
12427685
JAMA. 2000 Jun 28;283(24):3205-10
10866867
J Bone Miner Res. 2000 Apr;15(4):650-62
10780857
Osteoporos Int. 2003 Jun;14(4):273-82
12736772
Stat Med. 1999 Oct 30;18(20):2693-708
10521860
Stat Med. 1988 Aug;7(8):889-94
3413368
J Am Geriatr Soc. 1992 Sep;40(9):861-6
1512379
Arch Intern Med. 2000 Oct 9;160(18):2865
11025797
J Clin Epidemiol. 1992 Jul;45(7):769-73
1619456
Osteoporos Int. 2000;11(6):467-80
10982161
Biochem Biophys Res Commun. 2000 May 19;271(3):699-702
10814525
Inj Prev. 2002 Dec;8(4):276-9
12460961
Epidemiology. 1991 Mar;2(2):116-22
1932308
Lancet. 2000 Jun 24;355(9222):2218-9
10881898